Galectin Therapeutics (GALT)

• Market cap: $423M
• 1 day: 4.96%
• 5 days: 9.33%
• 1 month: 9.33%
• 3 months: 45.78%
• 6 months: 340.27%
• Year to date: 460.68%
• 1 year: 183.98%
• 5 years: 160.32%
• 10 years: 266.48%
• Sector: Healthcare
• Industry: Biotechnology

About: Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Employees: 15